China Biologic Products Holdings, Inc: Citic Capital Holdings Ltd Makes Purchase

June 18, 2018 - By Henry Gaston

The New Citic Capital Holdings Ltd Holding in China Biologic Products Holdings, Inc

Citic Capital Holdings Ltd reported SC 13D form with the SEC for China Biologic Products Holdings, Inc. Access it here: 000114420418034488. As reported by Citic Capital Holdings Ltd, the filler owns 5.1% or 1,680,863 shares of the Health Care–company.

China Biologic Products Holdings, Inc stake is new for [reportingPerson]. Date of activity: June 8, 2018. This shows Citic Capital Holdings Ltd’s positive view for China Biologic Products Holdings, Inc.

Reasons Why Citic Capital Holdings Ltd Bought – China Biologic Products Holdings, Inc Stock

Item 4. Purpose of Transaction

On June 11, 2018, CCREsubmitted a preliminary, non-binding letter (the “Proposal Letter”) to the Board of Directors of the Issuer(the “Board”). In the Proposal Letter, CCRE outlined its proposal (“Proposal”) for the Transaction(as defined below). Under the Proposal, CCRE proposes to acquire, all of the outstanding share capital of the Issuer not alreadyowned by CCRE and its affiliates (collectively “CITIC”) for US$110 in cash per Ordinary Share (the “Transaction”).In the Proposal Letter, CCRE stated that it intends to finance the Transaction with a combination of debt and equity. The Proposalalso provides that, among other things, (a) CITIC will need to conduct due diligence on the Issuer, and (b) CITIC will negotiatewith the Issuer to agree on, and enter into, definitive agreements with respect to the Transaction. In the Proposal Letter, CCREalso expressed its willingness to welcome members of the management of the Issuer and other shareholders of the Issuer in joiningCITIC to participate in the Transaction, and at the very least, it hopes that the existing key members of management can continueto lead the Issuer after the completion of the Transaction.

The Proposal and theTransaction are subject to a number of conditions, including, among other things, the negotiation and execution of definitive agreementsmutually acceptable in form and substance to the Issuer and CITIC and the redemption and termination of all preferred share purchaserights of the Issuer before any such right becomes exercisable. Neither the Issuer nor CITIC is obligated to complete the Transaction,and a binding commitment with respect to the Transaction will result only from the execution of definitive documents, and thenwill be on the terms provided in such documentation. CITIC reserves the right to withdraw the Proposal without further obligationof any kind at any time and for any reason or no reason.

References to theProposal Letter in this Schedule 13D are qualified in their entirety by reference to the Proposal Letter, which is attached heretoas an exhibit and incorporated herein by reference as if set forth in its entirety herein.

If the proposed Transaction is completed,the Ordinary Shares would be delisted from the NASDAQ Global Select Market, and the Issuer’s obligation to file periodicreports under the Securities Exchange Act of 1934, as amended, would terminate. In addition, consummation of the proposed Transactioncould result in one or more of the actions specified in clauses (a)-(j) of Item 4 of Schedule 13D, including the acquisition ordisposition of securities of the Issuer, a merger or other extraordinary transaction involving the Issuer, a change to the boardof directors of the Issuer (as the surviving company in the merger), and a change in the Issuer’s memorandum and articlesof association to reflect that the Issuer would become a privately held company.

CUSIP No. G21515104

SEC Form 13D.

Analysts await China Biologic Products Holdings, Inc. (NASDAQ:CBPO) to report earnings on August, 1. They expect $1.26 earnings per share, down 6.67 % or $0.09 from last year’s $1.35 per share. CBPO’s profit will be $41.84M for 16.28 P/E if the $1.26 EPS becomes a reality. After $1.21 actual earnings per share reported by China Biologic Products Holdings, Inc. for the previous quarter, Wall Street now forecasts 4.13 % EPS growth.

The stock decreased 0.86% or $0.71 during the last trading session, reaching $82.04. About 431,845 shares traded or 54.34% up from the average. China Biologic Products Holdings, Inc. (NASDAQ:CBPO) has declined 30.31% since June 18, 2017 and is downtrending. It has underperformed by 42.88% the S&P500.

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. The company has market cap of $2.72 billion. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. It has a 35.47 P/E ratio. The firm also provides human immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus.

China Biologic Products Holdings, Inc. (NASDAQ:CBPO) Ratings Coverage

Among 2 analysts covering China Biologic (NASDAQ:CBPO), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. China Biologic has $105.0 highest and $97.0 lowest target. $101’s average target is 23.11% above currents $82.04 stock price. China Biologic had 3 analyst reports since March 2, 2018 according to SRatingsIntel. The stock of China Biologic Products Holdings, Inc. (NASDAQ:CBPO) has “Hold” rating given on Monday, May 14 by Jefferies. The firm has “Buy” rating given on Thursday, March 15 by Jefferies.

More news for China Biologic Products Holdings, Inc. (NASDAQ:CBPO) were recently published by:, which released: “Analysis: Positioning to Benefit within China Biologic Products, Merus NV, Adient, G1 Therapeutics, Westport Fuel, and …” on June 06, 2018.‘s article titled: “China Biologic Products (CBPO) Receives CFDA Clinical Trial Approval for Human Fibrin Sealant” and published on June 11, 2018 is yet another important article.

China Biologic Products Holdings, Inc. (NASDAQ:CBPO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: